Labopharm Inc. (Nasdaq: DDSS, TSE: DDS) has presented the 12-week safety data from its three U.S. Phase III clinical trials for once-daily tramadol in a poster at the recent 17th Annual Clinical Meeting of the American Academy of Pain Management (AAPM), held September 7 - 9, 2006 in Orlando, Florida.
According to James R. Howard-Tripp, President and Chief Executive Officer of Labopharm Inc.:
"The data from these studies further confirms our belief that our once-daily formulation of tramadol will be well positioned in the market as we continue to pursue commercialization globally.”
In the said clinical trials, the efficacy and safety of Labopharm's once-daily formulation of tramadol was evaluated in 1763 patients with osteoarthritis of the knee.
Compared with the safety profiles described in the literature pertaining to other tramadol formulations, traditional opioids and NSAIDS, Labopharm's once daily tramadol provides a safe alternative for pain management.
Read more details from the press release.
Comment Preview